UGT1A1*28 polymorphisms: A potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer

Pharmacogenomics

Volumn 15, Issue 9, 2014, Pages 1171-1174

  Liu, Xiang ^a   Xu, Wei ^b,c  

^a HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

colorectal cancer; efficacy; irinotecan; pharmacological biomarker; toxicity; UGT1A1*28

Indexed keywords

FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; PHARMACOLOGICAL BIOMARKER; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; GLUCURONOSYLTRANSFERASE; TUMOR MARKER; UGT1A1 ENZYME;

ALLELE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; NEUTROPENIA; OVERALL SURVIVAL; REVIEW; TREATMENT OUTCOME; UGT1A1 GENE; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; ENZYMOLOGY; GENETICS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; HUMANS; POLYMORPHISM, GENETIC; TOPOISOMERASE I INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906546966     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.78     Document Type: Review

References (18)

1. Palomaki GE, Bradley LA, Douglas MP et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med. 11, 21-34 (2009
2. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355, 1041-1047 (2000
3. Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis. 14, 3-17 (2012
4. Toffoli G, Cecchin E, Corona G et al. Pharmacogenetics of irinotecan. Curr. Med. Chem. Anticancer Agents 3, 225-237 (2003
5. Ando Y, Saka H, Ando M et al. Polymorphisms of UDP glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000
6. Innocenti F, Undevia SD, Ramirez J et al. A Phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin. Pharmacol. Ther. 76, 490-502 (2004
7. Marcuello E, Altes A, Menoyo A et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682 (2004
8. Rouits E, Boisdron-Celle M, Dumont A et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151-5459 (2004
9. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: Practical pharmacogenomics arrives in cancer therapy. J. Clin. Oncol. 24, 4534-4538 (2006
10. Hoskins JM, Goldberg RM, Qu P et al. UGT1A1 28 genotype and irinotecan-induced neutropenia: Dose matters. J. Natl Cancer Inst. 99, 1290-1295 (2007
11. Zhe-Yi H, Qi Y, Pei Q et al. Dose-dependent association between UGT1A1 28 genotype and irinotecan-induced neutropenia: Low doses also increase risk. Clin. Cancer Res. 16, 3832-3842 (2010
12. Hu ZY, Yu Q, Zhao YS. Dose-dependent association between UGT1A1 28 polymorphism and irinotecan-induced diarrhoea: A meta-Analysis. Eur. J. Cancer 46, 1856-1865 (2010
13. Liu X, Cheng D, Kuang Q et al. Association of UGT1A1 28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: A meta-Analysis in Caucasians. Pharmacogenomics J. 14, 120-129 (2014
14. Dias MM, McKinnon RA, Sorich MJ. Impact of the UGT1A1 28 allele on response to irinotecan: A systematic review and meta-Analysis. Pharmacogenomics 13, 889-899 (2012
15. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004
16. Berg AO, Armstrong K, Botkin J et al. Recommendations from the EGAPP working group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet. Med. 11, 15-20 (2009
17. Liu X, Cheng D, Kuang Q et al. Association between UGT1A1 28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: A meta-Analysis in Caucasians. PLoS ONE 8, e58489 (2013
18. Shulman K, Cohen I, Barnett-Griness O et al. Clinical implications of UGT1A1 28 genotype testing in colorectal cancer patients. Cancer 117, 3156-3162 (2011